Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS (DRINOTES)

2 de novembro de 2026 atualizado por: University Hospital, Clermont-Ferrand

Proof-of-Concept Study Evaluating the Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS Requiring Surgical Treatment.

Polycystic Ovary Syndrome (PCOS) is a common condition among young women (the leading endocrine disorder) and is responsible for 70% of anovulatory infertility cases. Clinically, it has been defined since 2003 by the Rotterdam criteria, according to the French College of Obstetricians and Gynecologists. PCOS represents a significant challenge in reproductive medicine, as it is associated with infertility rates ranging from 20% to 74%. Ovarian stimulation is the first-line treatment for PCOS, as no etiological treatment is available. The first-line pharmacological treatment is Clomiphene Citrate. In cases where Clomiphene Citrate fails, the second-line treatment is ovarian drilling. Traditionally, ovarian drilling was performed via laparoscopy or fertiloscopy. Fertiloscopy had the advantage of being quicker and scarless for patients, with reported failure and conversion rates to laparoscopy of 10% to 20% depending on the studies. However, fertiloscopy is no longer practiced due to the discontinuation of the device. With the advent of vNOTES laparoscopy (Vaginal Natural Orifice Transluminal Endoscopic Surgery) in the 2010s for benign gynecological conditions, the possibility of a new vaginal approach for ovarian drilling is now being considered. The Primary Objective is to Evaluate the efficacy of ovarian drilling via vNOTES laparoscopy in terms of resumption of spontaneous ovulatory cycles in PCOS patients requiring surgical treatment.

Study Type:

Single-center, randomized, controlled, two-arm, proof-of-concept study. Number of Centers: 1

Study Description:

During the gynecology consultation, if an indication for ovarian drilling is established, the patient will be invited to participate in the study protocol. The study information sheet, detailing the study procedures and objectives, along with the consent form, will be provided to the patient.

A second consultation with the investigator will be scheduled to address any questions following a reflection period. If the patient consents, both she and the investigator will sign the consent form.

Randomization will be conducted using REDCap® software. The patient will then be assigned to either the vNOTES group or the laparoscopy group. Surgery will be performed by surgeons designated as "experts" in the respective surgical approach. The procedure will follow the standard techniques of the department.

Ovulatory cycle resumption will be assessed 6 months postoperatively during a follow-up consultation.

Visão geral do estudo

Descrição detalhada

Latest State of Scientific Knowledge Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in young women (5% of women of reproductive age) and is responsible for 70% of anovulatory infertility cases.

Since 2003, it has been defined according to the College of Obstetricians and Gynecologists of France by the Rotterdam criteria, which were revised by ESHRE in 2023.

According to these criteria, to diagnose PCOS, it is necessary to present at least two of the following three criteria and to have excluded other diagnoses:

Menstrual cycle abnormalities (amenorrhea, oligomenorrhea, long cycles) Clinical (hirsutism, acne, hair loss) or biological hyperandrogenism (elevated levels of free and total testosterone) Presence of polycystic ovaries on ultrasound: at least 12 follicles measuring 2 to 9 mm in diameter in each ovary or more than 20 follicles regardless of size. The number of follicles is more relevant than ovarian volume .

PCOS is a significant concern for reproductive medicine as it is associated with 20% to 74% infertility due to arrested follicular maturation caused by a multifactorial mechanism, particularly involving hyperandrogenism caused by excessive androgen production by the ovarian theca cells.

Ovarian stimulation is the first-line treatment for infertility related to PCOS as there is no etiological treatment. The first-line treatment is Clomiphene Citrate. It is a SERM that acts by inhibiting the negative feedback of estrogens on FSH. In case of failure, second-line treatment is ovarian drilling or gonadotropin stimulation according to ESHRE 2018 recommendations. Ovarian drilling involves making perforations in the ovarian stroma to destroy approximately 5% of the cortex of each ovary. It is recommended to use bipolar energy rather than monopolar or CO2 laser energy to reduce the risk of adhesions. Moreover, bipolar energy decreases the diffusion of energy compared to monopolar, thus limiting the reduction of the ovarian follicle pool. Although the mechanism remains unclear, it appears that the destruction of ovarian stroma by microperforations reduces androgen levels, increases FSH levels, and promotes follicular maturation.

The first ovarian drilling by laparoscopy was described in 1984 by Gjonnaess and his team. It was traditionally performed via laparoscopy or fertiloscopy. The latter technique is no longer practiced due to the discontinuation of the device.

More recently, in the 2010s, a new minimally invasive laparoscopic technique, vNOTES (Vaginal Natural Orifice Transluminal Endoscopic Surgery), was developed, using a natural orifice: the vagina. This method was first developed in Taiwan in 2012, then in Belgium.

With the development of the vNOTES laparoscopic technique for benign gynecological pathologies, particularly adnexal pathologies, the question arises of a new approach for ovarian drilling. Indeed, data on its use in the context of ovarian drilling are very limited, but initial results show a minimally invasive approach with good access to the pelvic cavity, minimal scarring, and reduced postoperative pain . The ovarian drilling technique using vNOTES was recently described by Professor Fernandez and his team and presented in a video at the SCGP congress in 2022 .

Hypotheses and Objectives The study is based on the hypothesis that ovarian drilling via vaginal vNOTES laparoscopy is at least as effective as the conventional laparoscopic technique in terms of resumption of ovulatory cycles. The objective is to evaluate the effectiveness of vaginal vNOTES laparoscopy compared to abdominal laparoscopy for ovarian drilling in women with polycystic ovary syndrome undergoing medically assisted reproduction.

Summary of Expected Benefits and Risks for Participants Expected benefits for patients in the VNotes group: shorter operative duration, less significant pain evolution, and aesthetic benefits.

Risks: The risks are those associated with anesthesia and surgery: hemorrhage, infection, digestive, vascular, or urinary tract injury, vaginal scar dehiscence. The additional risks of laparoscopy are those associated with trocars: hemorrhage, infection, herniation, and scar dehiscence.

The additional risk of vNOTES is the inability to complete the procedure, requiring conversion to laparoscopy.

Expected Outcomes If the ovarian drilling technique via VNotes proves to be as effective as laparoscopy, it would legitimize the development of an innovative technique combining good anatomical visualization, absence of abdominal scarring, and better outcomes in the context of assisted reproduction, as well as improved postoperative recovery for patients, with equivalent results in terms of ovulation resumption and pregnancy.

Tipo de estudo

Intervencional

Inscrição (Estimado)

48

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 43 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • PCOS defined by Rotterdam criteria requiring ovarian drilling after failure of first-line medical treatment
  • Primary or secondary infertility
  • Able to provide informed consent to participate in the research

Exclusion Criteria:

  • History of ovarian drilling
  • History of multiple pelvic surgeries
  • Current pregnancy or breastfeeding
  • Need for another associated surgical procedure other than hysteroscopy (hysteroscopy, neostomy)
  • Other infertility factors requiring IVF management
  • Contraindication to either surgical approach (laparoscopy or vNOTES):
  • History of upper genital tract infection
  • Confirmed or suspected recto-vaginal endometriosis on clinical examination
  • History of rectal surgery
  • Promontofixation
  • Virgin patient
  • Any concomitant pathology deemed incompatible with the study
  • Patients not affiliated with the social security system
  • Patients not speaking French
  • Patients under guardianship, curatorship, deprived of liberty, or under judicial protection
  • Refusal to participate

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: ovarian drilling by abdominal laparoscopy

Ovarian drilling procedure by abdominal laparoscopy

1st stage of surgery Patient in gynecological position, double skin cleansing with alcoholic Betadine and vaginal cleansing with dermal Betadine, placement of sterile drapes.

Urinary evacuation catheterization. Introduction of a diagnostic hysteroscope via vaginoscopy. Progress through the cervical canal. Exploration of the uterine cavity. Cannulation using a manipulator to perform a tubal blue test. 2nd stage of surgery: Patient in supine position, legs slightly abducted and semi-flexed. Insufflation of pneumoperitoneum in left hypochondrium with Palmer needle after satisfactory syringe safety test, up to a pressure of 20 mmHg. Trans-umbilical coeliotomy allowing passage of a 10 mm optical trocar after infiltration of the tract with Naropein 7.5 mg/ml.

Placement of two 5 mm operating trocars in the left iliac fossa and suprapubic area after infiltration of the tracts with Naropein 7.5 mg/ml.

Single-stitch closure with Filapeau 3/0.

Ovarian drilling procedure by abdominal laparoscopy versus ovarian drilling procedure by laparoscopic Vnotes .

see each arm for details for each intervention

Experimental: Ovarian drilling by vaginal laparoscopy VNotes

Patient in gynecological position, double scrubbing of skin with alcoholic Betadine and vaginal with dermal Betadine, sterile drapes in place Urinary evacuation catheterization Introduction of a diagnostic hysteroscope via vaginoscopy Progress through the cervical canal Exploration of the uterine cavity Para-cervical block, uterine cannulation using a manipulator or a pediatric foley probe to perform a tubal blue test.

Placement of a Pozzi on the posterior lip of the cervix. Vaginal incision 1 cm below the cervix for 2 cm, opening the peritoneum with scissors vNOTES Gelpoint device inserted Trendelenburg position Insufflation of pneumoperitoneum(8 mm Hg) Exploration of abdominal cavity Bilateral ovarian drilling; approx. 12 to 15 micro-perforations on each side using the bipolar Versapoint inserted in the Bettochi and regular saline instillation Systematic tubal blue test Removal of the device Exsufflation of pneumoperitoneum Closure of the cul de sac of Douglas with a MONOCRYL 2/0

Ovarian drilling by vaginal laparoscopy VNotes

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
The resumption (or not) of an ovulatory cycle
Prazo: at the 6 months follow-up visit

The resumption (or not) of an ovulatory cycle will be evaluated during the 6 months follow-up visit after the intervention. The resumption of cycles is defined by cycles lasting more than 3 months, an elevated progesterone level, or the presence of a corpus luteum on ultrasound."

at the 6 months follow-up visit

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Pain assessment
Prazo: 1 hour during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 1 hour during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

1 hour during ambulatory care
pain assessment
Prazo: 6 hours during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 6 hours during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

6 hours during ambulatory care
pain assessment
Prazo: on day 1 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient through a questionnaire sent to the patients on Day 1 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 1 after the intervention
pain assessment
Prazo: on day 7 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient on Day 7 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 7 after the intervention
pain assessment
Prazo: at the postoperative follow-up visit (1 month)

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient during the postoperative follow-up visit. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

at the postoperative follow-up visit (1 month)
The use of analgesics
Prazo: up to 2 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 2 hours postoperatively

up to 2 hours postoperatively
The use of analgesics
Prazo: up to 24 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 24 hours postoperatively

up to 24 hours postoperatively
The use of analgesics
Prazo: postoperatively on Day 1

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on Day 1.

postoperatively on Day 1
The use of analgesics
Prazo: postoperatively on Day 7

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on day 7

postoperatively on Day 7
The use of analgesics
Prazo: at the postoperative follow-up visit (1 month)

For each arm: The use of analgesics (yes/no) recorded at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The operative duration
Prazo: peroperatively

For each arm: The operative duration from incision to closure recorded in the operating room, as well as the operative duration from the introduction of the Palmer needle in laparoscopy and the vaginal incision in VNotes until closure

peroperatively
Rehospitalization due to complications
Prazo: at the postoperative follow-up visit (1 month)

for each arm: Rehospitalization due to complications from the operation within the month following the procedure (yes/no), at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
Extension of the initial sick leave (yes/no)
Prazo: at the postoperative follow-up visit (1 month)

For each arm: Extension of the initial sick leave (yes/no), assessed at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The presence of intraoperative complications
Prazo: during the intervention

for each arm: The presence of intraoperative complications recorded during the intervention according to the Clavien-Dindo classification, including whether a conversion occurred, and the number of such complications

during the intervention
extension of the ambulatory stay (yes/no)
Prazo: Upon discharge from hospitalization (assessed up to 5 days)

For each arm: The use of an extension of the ambulatory stay (yes/no) and the total duration of hospitalization in days and hours

Upon discharge from hospitalization (assessed up to 5 days)
The occurrence of a pregnancy
Prazo: one year after the 6 months follow-up visit

The occurrence of a spontaneous pregnancy, IVF, twin pregnancy, or OHSS if IVF, assessed one year after the 6 months follow-up visit

one year after the 6 months follow-up visit
The measurement of AMH
Prazo: at the preoperative visit (1 month before the intervention)

The measurement of AMH in nanograms/mL at the preoperative visit (1 month before the intervention)

at the preoperative visit (1 month before the intervention)
The measurement of AMH
Prazo: at the postoperative follow-up visit (1 month)

The measurement of AMH in nanograms/mL at the postoperative follow-up visit (1month).

at the postoperative follow-up visit (1 month)
The measurement of AMH
Prazo: at the 6 Months follow-up visit

The measurement of AMH in nanograms/mL at the Month 6 follow-up visit

at the 6 Months follow-up visit
Satisfaction assessment
Prazo: at the postoperative follow-up visit (1 month)

Satisfaction assessment through the SF-36 questionnaire at the postoperative follow-up visit

at the postoperative follow-up visit (1 month)
Satisfaction assessment
Prazo: at the 6 Months follow-up visit

Satisfaction assessment through the SF-36 questionnaire at the 6 Months follow-up visit

at the 6 Months follow-up visit

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Anne-Sophie Gremeau, University Hospital, Clermont-Ferrand

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

14 de março de 2025

Conclusão Primária (Estimado)

14 de setembro de 2030

Conclusão do estudo (Estimado)

14 de setembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

19 de setembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de novembro de 2026

Primeira postagem (Real)

6 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever